by SignalFactory · December 22, 2021 | 09:24:45 UTC
The FDA appears poised to approve the use of both Pfizer’s and Merck’s COVID-19 pills. Learn how the new medicines will affect treatment for the coronavirus.
The FDA will likely announce the approval of Pfizer’s Paxlovid pill, developed to treat infections of COVID-19, as well as a competing pill from Merck. Bloomberg reported the news Tuesday morning, citing “people familiar with the matter” who asked not to be identified.
Last week Pfizer announced that Paxlovid, its proposed COVID-19 oral medication, reduces the risk of hospitalization or death by 89% if administered within three days of symptoms.
If given within five days, the pill still reduced the risk of severe reaction by 88%, according to final study results. That’s up from the 85% efficacy rate reported in an interim analysis in November.
If approved by the Food and Drug Administration, the drug “could have a meaningful impact on the lives of many,” Pfizer CEO Albert Bourla said in a statement Tuesday. “Emerging variants of concern, like omicron, have exacerbated the need for accessible treatment options for those who contract the virus … We are confident that, if authorized or approved, this potential treatment could be a critical tool to help quell the pandemic.”
Paxlovid, which would fight the more severe symptoms of COVID-19, would be added to the arsenal of tools doctors have to battle the pandemic, along with the approved COVID vaccines from Moderna, Pfizer, and Johnson & Johnson.
What is Pfizer’s COVID-19 antiviral drug? In the US, the three approved COVID vaccines can prevent infection. But for those already infected, antiviral drugs could reduce the odds of serious symptoms, hospitalization, and death.
Nirmatrelvir, marketed under the brand name Paxlovid, is designed to block the activity of the SARS-CoV-2-3CL protease, an enzyme that the coronavirus needs to replicate. In clinical trials, taken in combination with ritonavir, a drug used to treat HIV, Paxlovid reduced the risk of hospitalization or death by 89% when taken within three days of symptoms, Pfizer said. (The ritonavir allows the medication to remain active in the body longer at higher concentrations.)
If the Paxlovid is approved, two 150mg tablets would be administered at the first sign of symptoms or a positive COVID-19 test result and continued over a five-day treatment course.
The pill has proven effective against COVID-19 variants of concern, including delta and the newer omicron strain, Pfizer said.
During clinical trials, reported side effects between those taking Paxlovid and those taking a placebo were about the same, according to the pharmaceutical company.
Pfizer Inc. (PFE) said that it will supply the United Kingdom an additional 2.5 million treatment courses of its investigational candidate PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets).
It is in addition to the 250,000 treatment courses previously contracted by the UK Government, pending authorization and recommendation for use, bringing the full amount of treatment courses to 2.75 million.
Pfizer expects to produce PAXLOVID up to 80 million courses of treatment by the end of 2022, with 30 million treatment courses available in the first half of the year.
If authorized or approved, Pfizer will offer oral antiviral therapy through a tiered pricing approach based on the income level of each country to promote equity of access across the globe. High and upper-middle-income countries will pay more than lower-income countries.
Pfizer noted that it continues to invest up to about $1 billion to support the manufacturing and distribution of PAXLOVID, including exploring potential contract manufacturing options. It has entered into agreements with multiple countries and has initiated bilateral outreach to approximately 100 countries around the world.
If authorized or approved, PAXLOVID will be administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice daily for five days. One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course.
Pfizer Long (Buy) Enter At: 59.62 T.P_1: 61.67 T.P_2: 65.99 T.P_3: 69.19 T.P_4: 72.18 T.P_5: 75.00 S.L: 52.75
All information on this website is of a general nature. The information is not adapted to conditions that are specific to your person or entity. The information provided can not be considered as personal, professional or legal advice or investment advice to the user.
Signal Factory is not represented as a registered investment consultant or brokerage dealer nor offers to buy or sell any of the financial instruments mentioned in the service offered.
While Signal Factory believes that the content provided is accurate, there are no explicit or implied warranties of accuracy. The information provided is believed to be reliable; Signal Factory does not guarantee the accuracy or completeness of the information provided. Third parties refer to Signal Factory to provide technology and information if a third party fails, and then there is a risk that the information may be delayed or not delivered at all.
All information and comments contained on this website, including but not limited to, opinions, analyzes, news, prices, research, and general, do not constitute investment advice or an invitation to buy or sell any type of instrument. Signal Factory assumes no responsibility for any loss or damage that may result, directly or indirectly, from the use or dependence on such information.
All information contained on this web site is a personal opinion or belief of the author. None of these data is a recommendation or financial advice in any sense, also within the meaning of any commercial act or law. Writers, publishers and affiliates of Signal Factory are not responsible for your trading in any way.
The information and opinions contained in the site are provided for information only and for educational reasons, should never be considered as direct or indirect advice to open a trading account and / or invest money in Forex trading with any Forex company . Signal Factory assumes no responsibility for any decisions taken by the user to create a merchant account with any of the brokers listed on this website. Anyone who decides to set up a merchant account or use the services, free of charge or paid, to any of the Forex companies mentioned on this website, bears full responsibility for their actions.
Any institution that offers a service and is listed on this website, including forex brokers, financial companies and other institutions, is present only for informational purposes. All ratings, ratings, banners, reviews, or other information found for any of the above-mentioned institutions are provided in a strictly objective manner and according to the best possible reflection of the materials on the official website of the company.
Forex trading is potentially high risk and may not be suitable for all investors. The high level of leverage can work both for and against merchants. Before each Forex investment, you should carefully consider your goals, past experience and risk level. The opinions and data contained on this site should not be considered as suggestions or advice for the sale or purchase of currency or other instruments. Past results do not show or guarantee future results.
Neither Signal Factory nor its affiliates ensure the accuracy of the content provided on this Site. You explicitly agree that viewing, visiting or using this website is at your own risk.